HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

prothrombin fragment 1.2

activates factor Xa-catalyzed prothrombin activation

Also Known As:

prothrombin activation fragment F1+2

Networked: 37 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Duncan, Alexander: 4 articles (03/2021 - 12/2018)
2.	Jules-Elysee, Kethy M: 2 articles (06/2022 - 12/2019)
3.	McLawhorn, Alexander S: 2 articles (06/2022 - 12/2019)
4.	Sculco, Thomas P: 2 articles (06/2022 - 12/2019)
5.	Guarner, Jeannette: 2 articles (03/2021 - 01/2021)
6.	Belagaje, Samir: 2 articles (01/2020 - 12/2018)
7.	Belair, Trina: 2 articles (01/2020 - 12/2018)
8.	Bianchi, Nicolas: 2 articles (01/2020 - 12/2018)
9.	Henriquez, Laura: 2 articles (01/2020 - 12/2018)
10.	Hoppensteadt, Debra: 2 articles (01/2020 - 07/2013)

Related Diseases

1.	Stroke (Strokes) 04/01/2000 - "Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies." 04/01/2000 - "The aim of this study was to determine whether the presence of aPL in young patients with stroke or transient ischemic attacks represents a possible cause of hypercoagulability as defined by ongoing thrombin formation with resultant elevation of prothrombin fragment 1.2 (F1.2) levels. " 12/01/2018 - "In a subset of consecutive patients, d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex and fibrin monomer (MOCHA panel) were obtained ≥2 weeks post-stroke and repeated ≥4 weeks later if abnormal; abnormal MOCHA panel was defined as ≥2 elevated markers which did not normalize when repeated. " 01/01/2020 - "Consecutive patients with cryptogenic stroke who met embolic stroke of undetermined source (ESUS) criteria from January 1, 2017, to October 31, 2018, underwent outpatient cardiac monitoring and the MOCHA profile (serum D-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex, and fibrin monomer) obtained ≥2 weeks after the index stroke; abnormal MOCHA profile was defined as ≥2 elevated markers. "
2.	Thrombophilia 04/01/2000 - "The aim of this study was to determine whether the presence of aPL in young patients with stroke or transient ischemic attacks represents a possible cause of hypercoagulability as defined by ongoing thrombin formation with resultant elevation of prothrombin fragment 1.2 (F1.2) levels. " 04/01/2002 - "The use of coagulation activation markers (soluble fibrin polymer, TpP, prothrombin fragment 1.2, thrombin-antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders."
3.	Myocardial Infarction 04/01/1992 - "Plasma concentrations of prothrombin fragment 1.2, a polypeptide released when prothrombin is activated by factor Xa, were measured in 22 patients with acute myocardial infarction before and after treatment with 100 mg of recombinant tissue-type plasminogen activator (rt-PA). " 09/01/1996 - "To investigate potential mechanisms of thrombin formation in vivo, to understand better the balance of coagulation and fibrinolysis during treatment with recombinant tissue-type plasminogen activator (rt-PA), and to investigate the role of hemostatic markers as predictors of clinical events, we measured 3 markers of procoagulant activity: fibrinopeptide A (FPA), thrombin-antithrombin III complexes (TAT), and prothrombin fragment 1.2 (F1.2), and a marker of fibrinogenolytic activity (B beta 1-42) in patients enrolled in the Thrombolysis in Myocardial Infarction (TIMI)-5 study. "
4.	Sepsis (Septicemia) 01/01/2020 - "To assess the effects of recombinant human soluble thrombomodulin treatment on 28-day all-cause mortality in subgroups categorized by baseline coagulation biomarker levels (prothrombin fragment 1.2, thrombin-antithrombin complex, D-dimer) in patients with sepsis-associated coagulopathy in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial (SCARLET) (NCT01598831). "
5.	Myocardial Ischemia (Ischemic Heart Diseases) 01/01/1994 - "Mehtods and Results: In a study of 36 patients (59.1+/- 11.0 years) with myocardial ischemia at rest participating in the Thrombolysis in Myocardial Ischemia (TIMI) IIIB trial, thrombin activity in plasma, as determined by fibrinopeptide A (FPA), prothrombin fragment 1.2 (F 1.2), and thrombin-antithrombin III complexes (TAT) concentrations, were found to be increased significantly when compared with healthy volunteers (p < 0.004). "

Related Drugs and Biologics

1.	Thrombin
2.	Fibrinopeptide A
3.	Antithrombin III
4.	fibrin fragment D (D-dimer)
5.	antithrombin III-protease complex
6.	Biomarkers (Surrogate Marker)
7.	Tissue Plasminogen Activator (Alteplase)
8.	Thrombomodulin
9.	Hemostatics (Antihemorrhagics)
10.	Antithrombins

Related Therapies and Procedures

1.	Heart-Assist Devices
2.	Aftercare (After-Treatment)